137 CME on Pharmacogenomics Testing Improves Knowledge, Competence, and Confidence Related to Implementing Testing in Practice.

STUDY OBJECTIVE(S): Pharmacogenomics (PGx) testing, in particular combinatorial PGx testing, represents a potential means for delivering personalized treatment selection for patients with psychiatric disorders. The goal of this educational intervention was to educate clinicians about the role of PGx testing in neuropsychiatric conditions such as MDD, how these novel tests may be implemented into clinical practice, and how results may be used to inform decision-making. METHOD: Psychiatrists (n=830) participated in an online enduring CME activity on PGx testing in psychiatric disorders *The format was a 30-minute 2-person discussion (launched December 7, 2018)*Data from this activity were collected for 30 days after launch*Effectiveness of education for the CME activities was analyzed using 3 multiple-choice and 1 self-efficacy question (5-point Likert-type scale), presented as pre-/post-CME repeated pairs*A paired samples t-test was conducted to examine improvements in mean confidence pre and postParticipant knowledge, competence, and confidence change in pre- to post-CME responses were calculated. RESULTS: Overall, 72% of psychiatrists (n=830) had knowledge or competence that was reinforced or improved as a result of education. FOLLOWING EDUCATION: *56% and 12% of psychiatrists had reinforcement and improvement, respectively, in knowledge related to the clinical benefits of PGx-guided treatment strategies*61% and 8% of psychiatrists had reinforcement and improvement, respectively, in competence related to interpreting PGx tests for patients with neuropsychiatric disorders*Within the group of psychiatrists with reinforced and improved knowledge/competence, there was a 30% increase in their confidence using PGx tests to help guide treatment decisions for patients with major depressive disorder (MDD) (M pre=2.14, post=2.77, scale 1 to 5)*Confidence in the use of PGx testing was correlated with likelihood of considering PGx testing for patients with MDD. CONCLUSIONS: Online CME aided in psychiatrists' knowledge, competence, and confidence in using pharmacogenomics testing in patients with psychiatric disorders. FUNDING ACKNOWLEDGEMENTS: Supported by an independent educational grant from Myriad Neuroscience, formerly Assurex Health.